---
title: "300026.SZ (300026.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300026.SZ/news.md"
symbol: "300026.SZ"
name: "300026.SZ"
parent: "https://longbridge.com/en/quote/300026.SZ.md"
datetime: "2026-05-20T22:54:09.041Z"
locales:
  - [en](https://longbridge.com/en/quote/300026.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300026.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300026.SZ/news.md)
---

# 300026.SZ (300026.SZ) — Related News

### [Why is Chase Sun's profit mediocre despite its scientific achievements reaching the top of the world? The answer lies in its transformation](https://longbridge.com/en/news/285474022.md)
*2026-05-07T02:28:24.000Z*
> Chase Sun Pharmaceutical will celebrate its 30th anniversary in 2026. Despite its sepsis treatment traditional Chinese m

### [Chase Sun released its first-quarter performance, with a net profit attributable to the parent company of 65.7148 million yuan, an increase of 8.93%](https://longbridge.com/en/news/284347104.md)
*2026-04-28T09:53:42.000Z*
> Chase Sun released its first quarter report for 2026, with operating revenue of 1.13 billion yuan, a year-on-year decrea

### [Chase Sun: Injectable Polymyxin E Methanesulfonate has obtained a clinical trial approval](https://longbridge.com/en/news/283493359.md)
*2026-04-21T11:50:01.000Z*
> Chase Sun announced that the company recently received the drug clinical trial approval notice issued by the National Me

### [Chase Sun released its 2025 annual performance, with a net profit attributable to the parent company of 18.4951 million yuan, a decrease of 13.85%](https://longbridge.com/en/news/283336506.md)
*2026-04-20T10:37:21.000Z*
> Chase Sun released its annual report for 2025, with operating revenue of 4.941 billion yuan, a year-on-year decrease of 

### [Chase Sun: Injectable Polymyxin E Methanesulfonate has obtained a clinical trial approval](https://longbridge.com/en/news/279915576.md)
*2026-03-20T09:13:03.000Z*
> Chase Sun recently received approval from the National Medical Products Administration to conduct clinical trials for it

### [Chase Sun: Subsidiary Huzhou Outlook Pharmaceutical Co., Ltd. Zinc Stearate Transfer "A" Approved for Listing](https://longbridge.com/en/news/279047551.md)
*2026-03-13T12:54:58.000Z*
> Chase Sun's subsidiary Huzhou Outlook Pharmaceutical Co., Ltd. has recently received approval from the National Medical